NCT03702036No Longer Available不适用
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
详细描述
Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts.
Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Managed Access Program for Momelotinib in MyelofibrosisPrimary MyelofibrosisMyelofibrosisNCT05582083GlaxoSmithKline
Approved For Marketing
不适用
Compassionate Use of 131I-MIBG for Patients With Malignant PheochromocytomaPheochromocytomaParagangliomaNCT01377532University of California, San Francisco
Approved For Marketing
不适用
Dupilumab Compassionate Use StudyAsthmaNCT03020810Sally E. Wenzel MD
已完成
2 期
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)NL-OMON52629Sierra Oncology, Inc.1
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-BGGlaxoSmithKline Research & Development Limited400